Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Number of employees : 97 735 people.
2018 2019 Delta CHF (in Million) % CHF (in Million) % Pharmaceuticals 46,520 81.8% 50,714 82.5% +9.02% Diagnostics 12,977 22.8% 13,037 21.2% +0.46%
2018 2019 Delta CHF (in Million) % CHF (in Million) % United States 28,081 49.4% 31,164 50.7% +10.98% Rest of Europe 9,842 17.3% 9,672 15.7% -1.73% Rest of Asia 7,705 13.6% 8,717 14.2% +13.13% Japan 4,490 7.9% 4,674 7.6% +4.1% Germany 3,179 5.6% 3,084 5% -2.99% Latin America 2,870 5% 2,858 4.6% -0.42% Africa, Australia and Oceania 1,474 2.6% 1,359 2.2% -7.8% Switzerland 924.00 1.6% 1,237 2% +33.87% Rest of North America 932.00 1.6% 986.00 1.6% +5.79%
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
1
702,562,700
694,641,595
98.9% 7,921,105
1.1% 83.6%
Stock B
1
160,000,000
26,314,116
16.4% 0
0.0%
Shareholders Roche Holding AG (CH0012032048) Roche Holding AG (US) Roche Holding AG (CH0012032113)
Name Equities % The Vanguard Group, Inc. 20,970,555
2.98% Norges Bank Investment Management 19,422,629
2.76% Fidelity Management & Research Co. LLC 14,596,113
2.08% UBS Asset Management Switzerland AG 11,490,139
1.64% BlackRock Fund Advisors 10,807,734
1.54% Credit Suisse Asset Management (Schweiz) AG 8,754,247
1.25% Massachusetts Financial Services Co. 7,312,199
1.04% Zürcher Kantonalbank (Investment Management) 7,186,115
1.02% Roche Holding AG 6,800,000
0.97% PRIMECAP Management Co. 5,560,379
0.79%
Name Equities % Allianz Global Investors U.S. LLC 14,117,800
0.25% Dodge & Cox 12,482,299
0.22% Fayez Sarofim & Co. 7,081,950
0.13% Harding Loevner LP 6,083,936
0.11% Parametric Portfolio Associates LLC 5,376,571
0.096% ARK Investment Management LLC 5,349,027
0.095% Mairs & Power, Inc. 4,976,619
0.089% Transamerica Investment Management LLC 4,973,036
0.088% AllianceBernstein LP 4,292,330
0.076% Jarislowsky, Fraser Ltd. 3,583,824
0.064%
Name Equities % Hoffmann Family 72,018,000
45.0% Novartis AG 53,332,863
33.3% Maja Oeri 8,091,900
5.06% APG Asset Management NV 2,429,743
1.52% Canada Pension Plan Investment Board 1,492,000
0.93% Schroder Investment Management Ltd. 921,942
0.58% J.O. Hambro Capital Management Ltd. 743,124
0.46% Wellington Management Co. LLP 703,471
0.44% The Vanguard Group, Inc. 685,779
0.43% RBC Global Asset Management (UK) Ltd. 591,680
0.37%
Name Equities % Valuation
Chugai Pharmaceutical Co., Ltd. (4519) 1,005,669,000 59.9% 53,602,559,968 USD Roche Holding AG (ROG) 6,800,000 0.97% 2,379,884,468 USD Aligos Therapeutics, Inc. (ALGS) 3,092,340 8.11% 85,503,201 USD Pandion Therapeutics, Inc. (PAND) 3,086,084 10.5% 45,828,347 USD Senseonics Holdings, Inc. (SENS) 28,345,276 11.5% 24,717,081 USD Millendo Therapeutics, Inc. (MLND) 1,089,180 5.73% 2,330,845 USD
Company contact information
Roche Holding AG
Grenzacherstrasse 124
Basel, Basel-Stadt (Basle Town) 4070
Phone : +41.61.688.11.11
Fax : +41.61.691.93.91
Web :
http://www.roche.com
AstraZeneca shares fall on 'hefty' $39-billion Alexion deal
Sector Pharmaceuticals - NEC
Connections : Roche Holding AG
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
